ClinConnect ClinConnect Logo
Search / Trial NCT06674551

Suprascapular and Axillary Versus Interscalene Blocks Regarding Phrenic Affection in Shoulder Surgeries

Launched by AIN SHAMS UNIVERSITY · Nov 4, 2024

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Interscalene Nerve Block Axillary Nerve Block Shoulder Surgery

ClinConnect Summary

This clinical trial is looking at the best way to manage pain during shoulder surgeries by comparing two different methods of nerve blocks. A nerve block is a procedure that helps to numb a specific area of the body to reduce pain. The researchers want to see whether a combination of suprascapular and axillary nerve blocks (which target specific nerves in the shoulder) is better than the interscalene nerve block (which targets a nerve in the neck) in terms of keeping the diaphragm, the muscle used for breathing, functioning well.

To participate in this study, you need to be between 18 to 60 years old, in good overall health (classes I and II on the ASA scale), and have a body mass index (BMI) between 18 and 35. Certain conditions, like infections at the injection site, psychiatric issues, or severe lung diseases, would exclude you from participating. If you join the trial, you can expect to receive one of the two types of nerve blocks before your shoulder surgery, and the researchers will use ultrasound to monitor how well your diaphragm is working during the procedure. This study is important as it aims to improve pain management and minimize complications during shoulder surgeries.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients aged between 18 - 60 years old.
  • Both sexes.
  • ASA physical status classes I - II.
  • Body mass index: 18-35 kg/ m2.
  • Exclusion Criteria:
  • Infection at site of injection.
  • Psychiatric illness.
  • Central Nervous System Diseases like (epilepsy, stroke ...etc.) or neurological disease affecting patient's upper limb.
  • Dependence on opiates and psycho-dynamic medications.
  • Moderate to severe pulmonary disease.
  • Coagulopathy and bleeding disorders.
  • Allergies to drug used (Bupivacaine 0.5%).
  • Previous surgery at site of injection and history of radiotherapy.

About Ain Shams University

Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported